Background: Antithyroid antibodies increase the likelihood of developing overt hypothyroidism, but their clinical utility remains unclear. No large randomized controlled trial (RCT) has assessed whether older adults with subclinical hypothyroidism (SHypo) caused by autoimmune thyroid disease derive more benefits from levothyroxine treatment (LT4). Objective: To determine whether older adults with SHypo and positive antibodies derive more clinical benefits from LT4 than those with negative antibodies. Methods: We pooled individual participant data from two RCTs, Thyroid Hormone Replacement for Untreated Older Adults with Subclinical Hypothyroidism and IEMO 80+. Participants with persistent SHypo were randomly assigned to receive LT4 or placebo. We compared the effects of LT4 versus placebo in participants with and without anti–thyroid peroxidase (TPO) at baseline. The two primary outcomes were 1-year change in Hypothyroid Symptoms and Tiredness scores on the Thyroid-Related Quality-of-Life Patient-Reported Outcome Questionnaire. Results: Among 660 participants (54% women) ≥65 years, 188 (28.5%) had positive anti-TPO. LT4 versus placebo on Hypothyroid Symptoms lead to an adjusted between-group difference of −2.07 (95% confidence interval: −6.04 to 1.90) for positive antibodies versus 0.89 (−1.76 to 3.54) for negative antibodies (p for interaction = 0.31). Similarly, there was no treatment effect modification by baseline antibody status for Tiredness scores—adjusted between-group difference 1.75 (−3.60 to 7.09) for positive antibodies versus 1.14 (−1.90 to 4.19) for negative antibodies (p for interaction = 0.98). Positive anti-TPO were not associated with better quality of life, improvement in handgrip strength, or fewer cardiovascular outcomes with levothyroxine treatment. Conclusions: Among older adults with SHypo, positive antithyroid antibodies are not associated with more benefits on clinical outcomes with LT4.

Thyroid antibodies and levothyroxine effects in subclinical hypothyroidism: A pooled analysis of two randomized controlled trials / Lyko, C.; Blum, M. R.; Abolhassani, N.; Stuber, M. J.; Del Giovane, C.; Feller, M.; Moutzouri, E.; Oberle, J.; Jungo, K. T.; Collet, T. -H.; den Elzen, W. P. J.; Poortvliet, R. K. E.; Du Puy, R. S.; Dekkers, O. M.; Trompet, S.; Jukema, J. W.; Aujesky, D.; Quinn, T.; Westendorp, R.; Kearney, P. M.; Gussekloo, J.; Van Heemst, D.; Mooijaart, S. P.; Bauer, D. C.; Rodondi, N.. - In: JOURNAL OF INTERNAL MEDICINE. - ISSN 0954-6820. - (2022), pp. N/A-N/A. [10.1111/joim.13544]

Thyroid antibodies and levothyroxine effects in subclinical hypothyroidism: A pooled analysis of two randomized controlled trials

Del Giovane C.;
2022

Abstract

Background: Antithyroid antibodies increase the likelihood of developing overt hypothyroidism, but their clinical utility remains unclear. No large randomized controlled trial (RCT) has assessed whether older adults with subclinical hypothyroidism (SHypo) caused by autoimmune thyroid disease derive more benefits from levothyroxine treatment (LT4). Objective: To determine whether older adults with SHypo and positive antibodies derive more clinical benefits from LT4 than those with negative antibodies. Methods: We pooled individual participant data from two RCTs, Thyroid Hormone Replacement for Untreated Older Adults with Subclinical Hypothyroidism and IEMO 80+. Participants with persistent SHypo were randomly assigned to receive LT4 or placebo. We compared the effects of LT4 versus placebo in participants with and without anti–thyroid peroxidase (TPO) at baseline. The two primary outcomes were 1-year change in Hypothyroid Symptoms and Tiredness scores on the Thyroid-Related Quality-of-Life Patient-Reported Outcome Questionnaire. Results: Among 660 participants (54% women) ≥65 years, 188 (28.5%) had positive anti-TPO. LT4 versus placebo on Hypothyroid Symptoms lead to an adjusted between-group difference of −2.07 (95% confidence interval: −6.04 to 1.90) for positive antibodies versus 0.89 (−1.76 to 3.54) for negative antibodies (p for interaction = 0.31). Similarly, there was no treatment effect modification by baseline antibody status for Tiredness scores—adjusted between-group difference 1.75 (−3.60 to 7.09) for positive antibodies versus 1.14 (−1.90 to 4.19) for negative antibodies (p for interaction = 0.98). Positive anti-TPO were not associated with better quality of life, improvement in handgrip strength, or fewer cardiovascular outcomes with levothyroxine treatment. Conclusions: Among older adults with SHypo, positive antithyroid antibodies are not associated with more benefits on clinical outcomes with LT4.
N/A
N/A
Thyroid antibodies and levothyroxine effects in subclinical hypothyroidism: A pooled analysis of two randomized controlled trials / Lyko, C.; Blum, M. R.; Abolhassani, N.; Stuber, M. J.; Del Giovane, C.; Feller, M.; Moutzouri, E.; Oberle, J.; Jungo, K. T.; Collet, T. -H.; den Elzen, W. P. J.; Poortvliet, R. K. E.; Du Puy, R. S.; Dekkers, O. M.; Trompet, S.; Jukema, J. W.; Aujesky, D.; Quinn, T.; Westendorp, R.; Kearney, P. M.; Gussekloo, J.; Van Heemst, D.; Mooijaart, S. P.; Bauer, D. C.; Rodondi, N.. - In: JOURNAL OF INTERNAL MEDICINE. - ISSN 0954-6820. - (2022), pp. N/A-N/A. [10.1111/joim.13544]
Lyko, C.; Blum, M. R.; Abolhassani, N.; Stuber, M. J.; Del Giovane, C.; Feller, M.; Moutzouri, E.; Oberle, J.; Jungo, K. T.; Collet, T. -H.; den Elzen, W. P. J.; Poortvliet, R. K. E.; Du Puy, R. S.; Dekkers, O. M.; Trompet, S.; Jukema, J. W.; Aujesky, D.; Quinn, T.; Westendorp, R.; Kearney, P. M.; Gussekloo, J.; Van Heemst, D.; Mooijaart, S. P.; Bauer, D. C.; Rodondi, N.
File in questo prodotto:
File Dimensione Formato  
Journal of Internal Medicine - 2022 - Lyko - Thyroid antibodies and levothyroxine effects in subclinical hypothyroidism A.pdf

accesso aperto

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 747.12 kB
Formato Adobe PDF
747.12 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1288247
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? ND
social impact